Not finding it? Sign in to also search OpenAlex live.
-
T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS2020 Schizophrenia Bulletin conference-abstract Medicine Schizophrenia research and treatment Open access
Jan P.A.M. Bogers, George Hambarian, Jentien M. Vermeulen, Lieuwe de Haan
2citations -
OP0261 TREAT-TO-TARGET DOSE REDUCTION AND WITHDRAWAL STRATEGY OF TNF INHIBITORS IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
C. Michielsens, N. Den Broeder, Frank H J van den Hoogen, E. Mahler, S. Teerenstra, Désirée van der Heijde, +2 more
0citations -
OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
R. B. M. Landewé, Désirée M F M van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip E Van den Bosch, Karl Gaffney, +5 more
1citations -
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Andrew Charles Perkins, Vincent Ribrag, William E. Shomali, Rosa María Ayala, Claire N. Harrison, Stephen T. Oh, +2 more
12citations -
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.2021 Journal of Clinical Oncology conference-abstract Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism
Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert‐Jan Creemers, Birgit A. L. M. Deiman, Jesse Joachim Swen, +9 more
4citations -
NP-012 Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan: a multicentre real-world study2026 conference-abstract Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism
Sofía L. J. Peeters, Niels Heersche, Doortje T.M.M. Böhm, S. Böhringer, Roselien Guiljam, Marije Joosse, +14 more
0citations -
Feasibility and clinical outcomes of imatinib personalized dosing in gastrointestinal stromal tumor patients.2025 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Maud B. A. van der Kleij, Eline L. Giraud, Niels A.D. Guchelaar, Kim Westerdijk, Marinda Meertens, Roos F. Bleckman, +12 more
1citations -
POS0205 SAFETY AND TOLERABILITY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES (ILDs) IN SUBGROUPS BY SEX AND AGE2022 Annals of the Rheumatic Diseases conference-abstract Medicine Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Open access
A. M. Hoffmann-Vold, E. Volkmann, Yannick Allanore, S. Assassi, Jeska de Vries‐Bouwstra, V. Smith, +4 more
0citations -
OP0272 PREDNISONE USE AND THE INCIDENCE OF HYPERGLYCEMIA OR DIABETES IN PATIENTS WITH RHEUMATOID ARTHRITIS; A 10-YEAR SUB ANALYSIS OF THE BeSt STUDY.2022 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
JA van der Pol, Sytske Anne Bergstra, Tom W. J. Huizinga, C. Allaart
0citations -
MPN-554: Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients With Myelofibrosis2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Tania Jain, Vikas Gupta, Haifa Kathrin Al‐Ali, Haris Ali, John O Mascarenhas, Francesco Passamonti, +22 more
0citations -
MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Andrew T Kuykendall, Francesca Palandri, Gregory Sumpao Vosganian, Aniket Bankar, Naveen Pemmaraju, Kristen Marie Pettit, +18 more
0citations -
Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis2023 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James K. McCloskey, Francesca Palandri, Steffen Koschmieder, +18 more
42citations -
A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.2020 Journal of Clinical Oncology conference-abstract Medicine Cancer Treatment and Pharmacology Open access
Michela Casanova, Christof Maria Kramm, Dirk Reinhardt, Franco Locatelli, David R. D’Adamo, Yan Jia, +6 more
2citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Cell death mechanisms and regulation
Shukaib Arslan, Giovanni Marconi, Giovanni Martinelli, Shaun A. Fleming, Antonio Curti, Shira Naomi Dinner, +19 more
5citations -
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, +26 more
19citations